Albumin-templated manganese carbonate nanoparticles for precise magnetic resonance imaging of acute myocardial infarction

Abstract

Myocardial infarction (MI) is a major cause of death worldwide. Early and precise diagnosis of myocardial viability after MI is extremely important for effective treatment and prognosis evaluation. Herein, we developed the BSA-templated manganese carbonate (MnCO3@BSA) nanoparticles as an MR imaging contrast agent for accurate detection of the infarcted regions. The chemophysical features, targeting capability toward the infarct, and biocompatibility were evaluated. The nanoparticles showed superior chemical stability. In vitro study suggested that the MnCO3@BSA nanoparticles do not enter normal cardiomyocytes. MR imaging indicated that the MnCO3@BSA with a high longitudinal ( r 1) relaxivity of 5.84 mM−1s−1 at physiological condition specifically accumulated into the infarcted regions of myocardial ischemia/reperfusion (I/R) mice. In addition, the MnCO3@BSA nanoparticles exhibited low cytotoxicity to cardiomyocytes, no damage to organs and good hemocompatibility. Thereby, the MnCO3@BSA nanoparticles manifested great potential as an extracellular contrast agent of MR imaging for sensitive and specific detection of the infarcted regions during acute myocardial I/R injury.

Novel cutting edge nano‐strategies to address old long‐standing complications in cardiovascular diseases. A comprehensive review

“…74 Additionally, non-invasive molecular imaging may play an important role as a therapeutic tool. Examples may include the release of pitavastatin by nanoparticles in lungs inhibiting pulmonary hypertension, 75 the use of magnetofluorescent nanoparticles and supermagnetic nanoparticles loaded with iron oxide (SPIONs) for the elimination of foam cells in atherosclerosis, 76 their use with antiintegrins inhibiting angiogenesis in peripheral vascular disease, 31 nanoparticles that release VEGF for the maintenance of cardiac function in AMI, 32 superparamagnetic nanoparticles conjugated with simvastatin into stem cells for the treatment of MI 33 or conjugated with superoxide dismutase to reduce the damage caused after reperfusion in the brain 77 (Table 1).…”

Engineered nanoparticles promote cardiac tropism of AAV vectors

“…This is a multispecies process because once optimal capsids are identified in mice, their translation to nonhuman primates and humans is not guaranteed [3]. For nanoparticle (NP) targeting, typical approaches include modification of the NP surface with an affinity ligand (antibody, peptide) that is designed to recognize targets in the heart [10][11][12]. Even though tissue specific targeting has been improved with active targeting strategies such as ligand-receptor recognition, it is often challenging to identify corresponding receptors on targeted cell types [13].…”